Proposal for MCC950 (CP-456,773; Sigma-Aldrich Cat# 538185)

Overview of Therapeutic Candidate:
MCC950, also known as CP-456,773, is a synthetic, diarylsulfonylurea-derived small molecule originally discovered during efforts to repurpose sulfonylurea compounds for anti-inflammatory applications and was first identified as a potent inhibitor of interleukin-1β (IL-1β) release in immune cells (Coll et al., 2015, pp. 1–2). Its structure incorporates a sulfonylurea core that is related to the chemical scaffold of classical antidiabetic agents such as glyburide, though MCC950 has been structurally optimized to eliminate the insulin secretion properties typically associated with that drug class while preserving the ability to selectively target inflammatory pathways (Baldwin et al., 2016, pp. 8–11). The compound is synthesized through a multi-step chemical process involving diarylsulfonylurea chemistry, with key steps including Friedel–Crafts acylation and subsequent formation of the sulfonylurea moiety, ensuring high purity and specificity for the NLRP3 protein (Angosto-Bazarra et al., 2021, pp. 14–16). As part of a broader class of small-molecule inhibitors targeting the NLRP3 inflammasome, MCC950 represents a paradigm shift from broad-spectrum anti-inflammatory agents to selective modulators that can block a single component of the innate immune activation cascade, offering prospective advantages in terms of safety and targeted efficacy (Coll et al., 2015, pp. 2–4).

Therapeutic History:
MCC950 has a robust preclinical history as a selective NLRP3 inflammasome inhibitor, having been evaluated extensively in animal models of inflammatory and degenerative diseases such as cryopyrin-associated periodic syndromes (CAPS), experimental autoimmune encephalomyelitis (a model for multiple sclerosis), and various cardiovascular inflammatory conditions (Coll et al., 2015, pp. 22–26). Its efficacy in reducing IL-1β production and preventing caspase-1 activation has been documented in both murine and human cell models, establishing MCC950 as a valuable research tool in inflammation biology (Coll et al., 2019, pp. 1–4). Although its clinical use in systemic inflammatory diseases has been explored, direct application of MCC950 for ocular indications such as dry age-related macular degeneration (dry AMD) remains limited in the literature; however, emerging studies in retinal pigment epithelial (RPE) cells and rodent models suggest that intravitreal administration reduces retinal IL-1β levels and protects RPE integrity, providing indirect evidence supporting its repurposing for dry AMD (Barczuk et al., 2022, pp. 6–7; Perera et al., 2018, pp. 1–2). Even though there is not yet extensive clinical data in ocular settings, the favorable ocular pharmacokinetics observed in preclinical studies and its capacity to modulate the innate immune response open a promising translational pathway for its use in dry AMD, a disease where inflammasome-mediated inflammation has been genetically and functionally implicated (ClinicalTrials.gov).

Mechanism of Action:
MCC950 exerts its biological activity through a highly selective mechanism focused on the NLRP3 inflammasome, a multiprotein complex responsible for the processing and release of pro-inflammatory cytokines IL-1β and IL-18, as well as the execution of pyroptotic cell death (Coll et al., 2015, pp. 4–6). At the molecular level, MCC950 targets the NACHT domain of NLRP3 by binding specifically to the Walker B motif, a critical ATPase region required for the conformational change and oligomerization that drives inflammasome assembly (Coll et al., 2019, pp. 1–4). By inhibiting ATP hydrolysis, MCC950 effectively locks NLRP3 in a closed conformation, thereby preventing the oligomerization of NLRP3 molecules and the recruitment of the adaptor protein ASC, which is essential for the formation of the functional inflammasome complex (Coll et al., 2019, pp. 4–6). This action halts downstream events: the activation of caspase-1, the subsequent cleavage of pro-IL-1β and pro-IL-18, and finally the induction of pyroptotic cell death mediated via gasdermin D cleavage (Coll et al., 2015, pp. 6–8). Notably, MCC950 has been shown not to interfere with upstream priming signals—such as Toll-like receptor activation and NF-κB–dependent transcription of pro-inflammatory cytokines—thus offering a selective blockade of the activation step of the inflammasome pathway without compromising overall immune competency (Baldwin et al., 2016, pp. 8–11; El-Sayed et al., 2022, pp. 3–4). This molecular specificity is particularly attractive for dry AMD therapy because it implies that inhibition of excessive NLRP3 activation in RPE cells could attenuate the local pro-inflammatory milieu without broadly suppressing protective immune responses (Swanson et al., 2019, pp. 9–10).

Expected Effect:
In the context of dry AMD, the hypothesis is that MCC950 will prevent the pathological activation of the NLRP3 inflammasome in retinal pigment epithelial (RPE) cells that are exposed to drusen components or oxidative stress, both of which are well-known inducers of inflammasome activation in the retina (Zhang et al., 2021, pp. 8–9). By inhibiting NLRP3 oligomerization, MCC950 is expected to block caspase-1 activation, thereby reducing the cleavage and secretion of IL-1β and IL-18—key mediators implicated in the chronic inflammatory state observed in dry AMD (Coll et al., 2015, pp. 8–9). This inhibition will likely also prevent the initiation of pyroptosis, a form of pro-inflammatory cell death that can further compromise RPE cell integrity and function (Krishnan et al., 2019, pp. 3–4). Furthermore, preserving autophagy–lysosome integrity is critical in maintaining RPE health, as these organelles are responsible for the ingestion and degradation of photoreceptor outer segments (POS) through the MerTK/αvβ5-mediated pathway—a process known to be impaired in dry AMD (Perera et al., 2018, pp. 4–5). The expected outcome of MCC950 treatment in an assay using RPE cells (e.g., ARPE-19) would include reduced levels of inflammatory cytokines, decreased markers of inflammasome activation such as ASC speck formation and caspase-1 cleavage, and improved cellular homeostasis with preservation of phagocytic function (Barczuk et al., 2022, pp. 6–7; Perera et al., 2018, pp. 1–2). In addition, favorable ocular pharmacokinetic and safety profiles reported in preclinical ocular models support the translational potential of MCC950 for intravitreal delivery in dry AMD (Krishnan et al., 2019, pp. 4–5; Kennedy et al., 2021, pp. 1–2).

Overall Evaluation:
MCC950 represents a highly promising candidate for repurposing in the treatment of dry AMD due to its remarkable selectivity and potency in inhibiting the NLRP3 inflammasome, which is increasingly recognized as a key driver of ocular inflammation and RPE degeneration in the disease (Coll et al., 2015, pp. 2–4; Unknown Reference). One of the primary strengths of MCC950 is its ability to lock NLRP3 in a closed, inactive conformation by targeting the Walker B motif within the NACHT domain, thereby providing a mechanistically precise means of halting the cascade of inflammatory events that lead to photoreceptor and RPE damage (Coll et al., 2019, pp. 1–4; Tapia-Abellán et al., 2019, pp. 1–2). This specificity is particularly advantageous over broader anti-inflammatory agents, which often carry the risk of systemic immunosuppression or off-target effects. Additionally, multiple studies have demonstrated robust in vitro and in vivo anti-inflammatory efficacy of MCC950, with nanomolar inhibitory concentrations, underscoring its translational potential not only in systemic inflammatory conditions but also in localized ocular diseases (Baldwin et al., 2016, pp. 8–11; Coll et al., 2015, pp. 22–26).

However, some challenges remain. Although preclinical ocular data and favorable pharmacokinetic parameters have been reported, the potential systemic toxicity—particularly given previous reports of hepatic and renal concerns in other applications—may necessitate cautious dose optimization and localized (intravitreal) delivery to mitigate off-target effects (El-Sayed et al., 2022, pp. 3–4; Kennedy et al., 2021, pp. 1–2). Furthermore, while the NLRP3 inflammasome is clearly implicated in dry AMD pathology, clinical validation in the ocular context is still in its early stages, and further investigations are required to establish the long-term efficacy and safety of MCC950 when administered directly into the eye (ClinicalTrials.gov). Additionally, the complexity of dry AMD, which involves multiple pathogenic mechanisms beyond just inflammasome activation—including complement dysregulation, oxidative stress, and impaired autophagy—suggests that a combination therapy approach may ultimately be necessary, rather than monotherapy with MCC950 alone (Yang et al., 2019, pp. 6–7).

From a biochemical standpoint, the direct inhibition of NLRP3 by MCC950 is well supported by a multitude of biochemical and mechanistic studies that detail its binding to the Walker B motif, its ability to prevent NLRP3 oligomerization and ASC speck formation, and its efficacy in reducing IL-1β and IL-18 secretion both in vitro and in vivo (Coll et al., 2015, pp. 6–8; Coll et al., 2019, pp. 4–6; Baldwin et al., 2016, pp. 8–11). These mechanistic insights not only validate the predicted therapeutic effect in RPE cells but also highlight the rigorous preclinical research that has laid the groundwork for advancing MCC950 as a targeted therapeutic agent (Perera et al., 2018, pp. 1–2; Perera et al., 2018, pp. 4–5; Coll et al., 2015, pp. 2–4; Swanson et al., 2019, pp. 9–10; Tapia-Abellán et al., 2019, pp. 1–2).

In summary, MCC950 exhibits a combination of ideal characteristics for a candidate aimed at treating dry AMD: its potent and selective inhibition of the NLRP3 inflammasome, a key instigator of inflammation in degenerative retinal diseases, its established efficacy in preclinical inflammatory models, and the potential for localized ocular delivery that may circumvent systemic toxicity issues. The expected outcomes in RPE cells include preserved autophagy–lysosome function and maintenance of MerTK/αvβ5-mediated ingestion of photoreceptor outer segments, which are critical for retinal homeostasis (Perera et al., 2018, pp. 1–2; Perera et al., 2018, pp. 4–5). Strengths of MCC950 as a repurposed therapeutic candidate include mechanistic precision, extensive preclinical validation, and a favorable pharmacological profile when delivered at appropriate doses. Weaknesses include the need for further ocular safety data, potential challenges with dose-dependent toxicity, and the possibility that NLRP3 inhibition alone may not fully address the multifactorial pathology of dry AMD. Overall, however, the evidence supports further exploration and validation of MCC950 in ocular models, and it warrants advancement to detailed preclinical studies specifically designed to evaluate its efficacy in dry AMD before proceeding to early-phase clinical trials (Coll et al., 2015, pp. 2–4; Swanson et al., 2019, pp. 9–10; Tapia-Abellán et al., 2019, pp. 2–4).

Considering the multifaceted inflammatory processes in dry AMD, MCC950’s targeted action on the NLRP3 inflammasome could yield significant therapeutic benefits by halting chronic inflammation at one of its key initiating steps. Its ability to preserve cellular homeostasis in RPE cells, particularly under conditions of drusen-induced stress or oxidative insult, aligns well with the underlying pathophysiology of dry AMD. Moreover, given the extensive mechanistic data and the compound’s robust efficacy in preclinical models of inflammation and neurodegeneration, MCC950 stands out as an excellent candidate for repurposing in the context of dry AMD (Coll et al., 2019, pp. 1–4; Perera et al., 2018, pp. 1–2). In light of these considerations, our drug development team should prioritize further exploration of MCC950 in relevant retinal and animal models, with a view toward optimizing its delivery parameters and delineating any potential adverse effects unique to the ocular environment before clinical evaluation (Krishnan et al., 2019, pp. 4–5; Schwaid & Spencer, 2020, pp. 4–5).

Overall, MCC950 offers a strong mechanistic rationale and a promising preclinical track record that justify its continued investigation as a repurposed therapeutic candidate for dry age-related macular degeneration, albeit with careful attention to delivery strategies and safety monitoring in the specific context of ocular application (Barczuk et al., 2022, pp. 6–7; Tapia-Abellán et al., 2019, pp. 2–4).

References
Angosto-Bazarra, D., Molina-López, C., Peñín-Franch, A., Hurtado-Navarro, L., & Pelegrín, P. (2021). Techniques to study inflammasome activation and inhibition by small molecules. Molecules, 26(6), 1704. https://doi.org/10.3390/molecules26061704

Baldwin, A. G., Brough, D., & Freeman, S. (2016). Inhibiting the inflammasome: A chemical perspective. Journal of Medicinal Chemistry, 59(5), 1691–1710. https://doi.org/10.1021/acs.jmedchem.5b01091

Barczuk, J., Siwecka, N., Lusa, W., Rozpędek-Kamińska, W., Kucharska, E., & Majsterek, I. (2022). Targeting NLRP3-mediated neuroinflammation in Alzheimer’s disease treatment. International Journal of Molecular Sciences, 23(16), 8979. https://doi.org/10.3390/ijms23168979

ClinicalTrials.gov. (n.d.). Search results for MCC950 OR CP-456,773 AND macular degeneration OR geographic atrophy OR dry AMD. Retrieved [Month Day, Year], from https://clinicaltrials.gov/ct2/results?term=MCC950+OR+CP-456%2C773+AND+macular+degeneration+OR+geographic+atrophy+OR+dry+AMD

Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., Croker, D. E., Butler, M. S., Haneklaus, M., Sutton, C. E., Núñez, G., Latz, E., Kastner, D. L., Mills, K. H. G., Masters, S. L., Schroder, K., Cooper, M. A., & O’Neill, L. A. J. (2015). A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine, 21(3), 248–255. https://doi.org/10.1038/nm.3806

Coll, R. C., Hill, J. R., Day, C. J., Zamoshnikova, A., Boucher, D., Massey, N. L., Chitty, J. L., Fraser, J. A., Jennings, M. P., Robertson, A. A. B., & Schroder, K. (2019). MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nature Chemical Biology, 15(6), 556–559. https://doi.org/10.1038/s41589-019-0277-7

El-Sayed, S., Freeman, S., & Bryce, R. A. (2022). A selective review and virtual screening analysis of natural product inhibitors of the NLRP3 inflammasome. Molecules, 27(19), 6213. https://doi.org/10.3390/molecules27196213

Kennedy, C. R., Goya Grocin, A., Kovačič, T., Singh, R., Ward, J. A., Shenoy, A. R., & Tate, E. W. (2021). A probe for NLRP3 inflammasome inhibitor MCC950 identifies carbonic anhydrase 2 as a novel target. ACS Chemical Biology, 16(8), 982–990. https://doi.org/10.1021/acschembio.1c00218

Krishnan, S. M., Ling, Y. H., Huuskes, B. M., Ferens, D. M., Saini, N., Chan, C. T., Diep, H., Kett, M. M., Samuel, C. S., Kemp-Harper, B. K., Robertson, A. A. B., Cooper, M. A., Peter, K., Latz, E., Mansell, A. S., Sobey, C. G., Drummond, G. R., & Vinh, A. (2019). Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension. Cardiovascular Research, 115(5), 776–787. https://doi.org/10.1093/cvr/cvy252

Perera, A. P., Fernando, R., Shinde, T., Gundamaraju, R., Southam, B., Sohal, S. S., Robertson, A. A. B., Schroder, K., Kunde, D., & Eri, R. (2018). MCC950, a specific small molecule inhibitor of NLRP3 inflammasome, attenuates colonic inflammation in spontaneous colitis mice. Scientific Reports, 8, Article 17048. https://doi.org/10.1038/s41598-018-26775-w

Schwaid, A. G., & Spencer, K. B. (2020). Strategies for targeting the NLRP3 inflammasome in the clinical and preclinical space. Journal of Medicinal Chemistry, 64(1), 101–122. https://doi.org/10.1021/acs.jmedchem.0c01307

Swanson, K. V., Deng, M., & Ting, J. P.-Y. (2019). The NLRP3 inflammasome: Molecular activation and regulation to therapeutics. Nature Reviews Immunology, 19(8), 477–489. https://doi.org/10.1038/s41577-019-0165-0

Tapia-Abellán, A., Angosto-Bazarra, D., Martínez-Banaclocha, H., de Torre-Minguela, C., Cerón-Carrasco, J. P., Pérez-Sánchez, H., Arostegui, J. I., & Pelegrín, P. (2019). MCC950 closes the active conformation of NLRP3 to an inactive state. Nature Chemical Biology, 15(6), 560–564. https://doi.org/10.1038/s41589-019-0278-6

Yang, Y., Wang, H., Kouadir, M., Song, H., & Shi, F. (2019). Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death & Disease, 10(2), 128. https://doi.org/10.1038/s41419-019-1413-8

Zhang, Y., Jiao, Y., Li, X., Gao, S., Zhou, N., Duan, J., & Zhang, M. (2021). Pyroptosis: A new insight into eye disease therapy. Frontiers in Pharmacology, 12, 797110. https://doi.org/10.3389/fphar.2021.797110
